Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Robert Baffi, PhD, MBA, a seasoned leader in the industry. This strategic addition underscores Neuvivo's commitment to advancing its mission and driving growth. Dr. Baffi brings over 30 years of extensive experience in the biopharmaceutical sector, having held key leadership positions at renowned companies such as BioMarin Pharmaceuticals, Inc. and Genentech, Inc. He has a proven track record in drug development, regulatory affairs, strategic partnerships and preparing the commercialization of products for rare diseases. Dr. Baffi will play a vital role in guiding Neuvivo as it continues to prepare for the FDA review of NP001 in ALS while also seeking to expand its portfolio. Ari Azhir, PhD, CEO, Neuvivo expressed: "We're thrilled to welcome Dr. Baffi to our Board at this critical moment as we continue to navigate the FDA approval process with the goal of bringing the promise of this meaningful and life-changing treatment to people living with ALS who so urgently need it." Dr. B
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's disease [Yahoo! Finance]Yahoo! Finance
- New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast CancerBusiness Wire
- Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dyno and Roche collaborate on neurological gene therapies [Yahoo! Finance]Yahoo! Finance